Drummond R, Baru A, Dutkiewicz M, et al. Physicians’ real-world experience with IDegLira: results of a European survey. BMJ Open Diabetes Research and Care 2018;6:e000531. doi: 10.1136/bmjdrc-2018-000531
The authors traced some formatting errors in figures 2 and 3. The correct versions are now available below:
Figure 2 Satisfaction of respondents with IDegLira compared with basal-bolus. HbA1c, glycated hemoglobin; IDegLira, insulin degludec/liraglutide.
Figure 3 Respondents’ perceptions on (A) the potential of IDegLira compared with basal-bolus therapy to improve patient motivation to reach their target blood glucose levels; and (B) concerns with IDegLira compared with basal-bolus therapy. GI, gastrointestinal; IDegLira, insulin degludec/liraglutide.